Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Lonza’s Global Subject Matter Expert for Endotoxin Detection Appointed Chair of ASMFC Horseshoe Crab Advisory Panel

Lonza Group
Posted on: 14 Nov 18

Walkersville, MD (USA) / Basel (CH), 14 November 2018 – Today Lonza announced the appointment of Allen Burgenson, Global Subject Matter Expert for Endotoxin Detection at Lonza, as Chair of the Horseshoe Crab Advisory Panel of the Atlantic States Marine Fisheries Commission (ASMFC). Burgenson was elected by his peers to this esteemed position on 26 September 2018 in recognition of more than 35 years of experience in the biomedical use of horseshoe crabs. The appointment also follows Burgenson’s 10-year long service as a member of the Horseshoe Crab Advisory Panel – a position he was previously appointed to by the Governor’s Office of Maryland.

The blood of horseshoe crabs is vital to the health and safety of humans as it is used in bacterial endotoxin testing workflows to help verify the microbial purity of vaccines, injectable drugs and medical devices. Natural perils and human activity increasingly threaten the viability of global horseshoe crab populations, which calls for sustainable collection approaches for LAL production and acceptance of recombinant technologies for endotoxin detection to maintain the safety of the world’s injectable pharmaceuticals.

The mission of the ASMFC Horseshoe Crab Advisory Panel is focused on the conservation of the horseshoe crab, while also maintaining availability of this important species to the biomedical industry, the birding community and fisheries. The horseshoe crab is one of the 27 nearshore species of which the conservation and management is coordinated by the ASMFC.

“It is a great honor to have been chosen to chair this group of dedicated professionals, with whom I share the same principles,” Burgenson said. “This appointment marks a very special milestone in my journey as a horseshoe crab conservationist, which started when I was a child flipping stranded horseshoe crabs on the beach during the spawning season while my dad fished on the New Jersey shore. I look forward to working with the panel to further protect this important species.”

More information about endotoxin testing and Lonza’s portfolio of products is available on this website:


About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at

Lonza Contact Information
Lonza Cologne GmbH
Petra Haberkamm
Manager Marketing Communications
Tel +49 221 991990

Lonza Group Ltd
Constance Ward
Head External Communications
Tel +41 61 316 8840

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

For more information:

Editor's Details

Aimilia Papanastasiou
BioStrata Ltd

Last updated on: 14/11/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.